Most Read Articles
Audrey Abella, 14 Sep 2020
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
Roshini Claire Anthony, 15 Feb 2021

Tranexamic acid, administered shortly after Caesarean delivery, may reduce the risk of postpartum haemorrhage (PPH), according to results of the TRAAP2* trial conducted in France.

24 Apr 2021
Combination treatment with three or more antihypertensive drugs provides greater blood pressure (BP)-lowering effect than monotherapy, results of a study have shown. However, the net benefit may be lessened when side effects are considered.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.

Product Highlight - FLAGYL

24 Jul 2020

Your Trusted Defender Against Amoebiasis1,2,3,4 is back! Now available in Drugstores Nationwide

  • Treatment of anaerobic protozoal infections such as amoebiasis (intestinal and extraintestinal), giardiasis, trichomoniasis, balantidiasis, blastocystiasis and dientamoebiasis; for treatment of bacterial infections, including Bacteroides fragilis and Clostridium tetanus.1
  • First and Trusted Metronidazole for generations2
  • No. 1 Metronidazole in the market3
  • No. 1 Metronidazole prescribed by physicians4

References:
1) Flagyl Suspension Prescribing Information, updated January 2020.
2) IQVIA Pack Launch Date.
3) IQVIA Retail Audit, MAT Feb 2020.
4) IQVIA PMDI MAT December 2019 | SAPH.MTDZ.20.05.0332| VERSION NO. 1.6 | 25 MARCH 2020

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Audrey Abella, 14 Sep 2020
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
Roshini Claire Anthony, 15 Feb 2021

Tranexamic acid, administered shortly after Caesarean delivery, may reduce the risk of postpartum haemorrhage (PPH), according to results of the TRAAP2* trial conducted in France.

24 Apr 2021
Combination treatment with three or more antihypertensive drugs provides greater blood pressure (BP)-lowering effect than monotherapy, results of a study have shown. However, the net benefit may be lessened when side effects are considered.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.